Applied DNA Sciences, Inc. and Alphazyme LLC (Alphazyme) announced the successful conclusion of the companies' previously announced Linea? RNAP manufacturing scale-up agreement. The joint process development project resulted in an over 70% reduction in Linea RNAP manufacturing costs and the manufacture of a quantity of Linea RNAP sufficient to support Applied DNA's anticipated near-term demand for critical starting material for mRNA production.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4114 USD | +0.96% |
|
-14.26% | -96.67% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-96.67% | 4.16M | |
-10.34% | 11.57B | |
-12.48% | 7.37B | |
+31.15% | 5.44B | |
+0.26% | 5.31B | |
-18.68% | 3.74B | |
+7.43% | 2.58B | |
-64.53% | 2.33B | |
+27.01% | 2.23B | |
-11.15% | 2.21B |
- Stock Market
- Equities
- APDN Stock
- News Applied DNA Sciences, Inc.
- Applied DNA Sciences, Inc. and Alphazyme LLC Conclude Linea (TM) RNAP Manufacturing Scale-Up Project, Deliver Substantial Improvement in Linea (TM) IVT Platform Economics